Antithrombotic therapy in patients with lower limb chronic ischemia: is therapy with aspirin alone sufficient?

• Andreychuk K.A.
• Sokurenko G.Yu.

Abstract

Peripheral artery diseases have increasingly been gaining in medical and social importance due to not only growing morbidity but also therapeutic outcomes not fully satisfying both clinicians and patients, especially those with manifestations of critical limb ischemia. Revascularizing interventions combined with optimal medicamentous treatment are the “gold standard” in treatment of symptomatic lesions of peripheral arteries. Along with it, risks for the development of thrombotic complications both in the zone of the reconstruction and in other vascular basins, negatively influence overall rates of patients’ mortality and disability. Antiplatelet agents have so far remained in fact the only substantiated from the point of view of evidence-based medicine therapeutic factor decreasing the risks for the development of thrombotic complications in this patient cohort. A series of other drugs influencing blood coagulation system, as well as a combination thereof, by the findings of hitherto performed trials failed to demonstrate sufficient efficacy and/or safety. Oral anticoagulants opened new possibilities for antithrombotic prevention and treatment and have widely been used in various cardiovascular diseases. The results of a series of trials the most significant of which may be considered VOYAGER PAD showed possibilities and feasibility of introducing anticoagulants into therapeutic regimens for patients with PAD. Safety and efficacy of treatment regimens envisaging a combination of antiplatelet drugs with rivaroxaban at a dose of 2.5 mg twice daily were demonstrated both for patients undergoing conservative treatment and those after endured endovascular revascularizing interventions.

Keywords:peripheral artery disease; atherosclerosis obliterans; COMPASS; VOYAGER PAD; rivaroxaban; aspirin; revascularization; critical ischemia

References

1. Fowkes G.R., Rudan D., Rudan I., et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382 (9901): 1329–1340. DOI: https://doi.org/10.1016/S0140-6736(13)61249-0

2.  GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390 (10100): 1211–1259. DOI: https://doi.org/10.1016/S0140-6736(17)32154-2

3. Hirsch A.T., Duval S. The global pandemic of peripheral artery disease. Lancet. 2013; 382 (9901): 1312–1314. DOI: https://doi.org/10.1016/S0140-6736(13)61576-7

4. Sampson U.K., Fowkes F.G., McDermott M.M., et al. Global and regional burden of death and disability from peripheral artery disease: 21 world regions, 1990 to 2010. Global Heart. 2014; 9 (1): 145–158. DOI: https://doi.org/10.1016/j.gheart.2013.12.008

5. Russian Statistical Yearbook 2020. Moscow. 2020; 700. (in Russian)

6.  Lapébie F-X., Aboyans V., Lacroix P., et al. External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry. European Journal of Vascular and Endovascular Surgery. 2021; 62 (3): 439–449. DOI: https://doi.org/10.1016/j.ejvs.2021.05.028

7. Norgren L., Hiatt W.R., Dormandy J.A., et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Journal of Vascular Surgery. 2007; 45 (Suppl): 5–67. DOI: https://doi.org/10.1016/j.jvs.2006.12.037

8. Diehm C., Allenberg J.R., Pittrow D., et al. Mortality and Vascular Morbidity in Older Adults With Asymptomatic Versus Symptomatic Peripheral Artery Disease. Circulation. 2009; 120: 2053–2061. DOI: https://doi.org/10.1161/circulationaha.109.865600

9. Mahoney E.M., Wang K., Keo H.H., et al. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circulation: Cardiovascular Quality and Outcomes. 2010; 3 (6): 642–651. DOI: https://doi.org/10.1161/circoutcomes.109.930735

10. Sigvant B., Hasvold P., Kragsterman B., et al. Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study. Journal of Vascular Surgery. 2017; 66 (2): 507–514. DOI: https://doi.org/10.1016/j.jvs.2017.01.067

11. Natsional’nye rekomendatsii po diagnostike i lecheniyu zabolevanii arterii nizhnikh konechnostey (in Russian). Moskva. 2019; 89. (in Russian)

12. Conte M.S., Bradbury A.W., Kolh P., et al. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. European Journal of Vascular and Endovascular Surgery. 2019; 58 (1S): S1–S109. DOI: https://doi.org/10.1016/j.ejvs.2019.05.006

13. Sigvant B., Lundin F., Wahlberg E. The Risk of Disease Progression in Peripheral Arterial Disease is Higher than Expected: A Meta-Analysis of Mortality and Disease Progression in Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery. 2016; 51 (3): 395–403. DOI: https://doi.org/10.1016/j.ejvs.2015.10.022

14. Armstrong E.J., Ryan M.P., Baker E.R., et al. Risk of major amputation or death among patients with critical limb ischemia initially treated with endovascular intervention, surgical bypass, minor amputation, or conservative management. Journal of Medical Economics. 2017; 20 (11): 1148–1154. DOI: https://doi.org/10.1080/13696998.2017.1361961

15. Ziegler-Graham K., MacKenzie E.J., Ephraim P.L., et al. Estimating the prevalence of limb loss in the United States: 2005 to 2050. Archives of Physical Medicine and Rehabilitation. 2008; 89 (3): 422–429. DOI: https://doi.org/10.1016/j.apmr.2007.11.005

16. Aboyans V., Ricco J.B., Bartelink M.E.L., et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal. 2018; 39 (9): 763–816. DOI: https://doi.org/10.1093/eurheartj/ehx095

17. Pokrovsky AV, Golovjuk AL. Sostoyanie sosudistoy khirurgii v Rossiyskoy Federatsii v 2018 godu. Angiology and Vascular Surgery. 2019; 25 (2 Suppl.): 1–49. (in Russian)

18. Hess C.N., Wang T.Y., Weleski Fu J., et al. Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization. Journal of the American College of Cardiology. 2020; 75 (5): 498–508. DOI: https://doi.org/10.1016/j.jacc.2019.11.050

19. Hess C.N., Huang Z., Patel M.R., et al. Acute limb ischemia in peripheral artery disease: insights from EUCLID. Circulation. 2019; 140 (7): 556–565. DOI: https://doi.org/10.1161/circulationaha.119.039773